Page 19 - Read Online

Ciardullo et al. Metab Target Organ Damage 2024;4:30 https://dx.doi.org/10.20517/mtod.2024.39 Page 13 of

Int 2020;40:3018-30. DOI PubMed
72. Lin S, Huang J, Wang M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 2020;40:2082-9. DOI
PubMed
73. Ciardullo S, Perseghin G. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States
population. Liver Int 2021;41:1290-3. DOI PubMed
74. Hagström H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore
identical. J Hepatol 2024;80:e76-7. DOI PubMed
75. Ratziu V, Boursier J; AFEF Group for the Study of Liver Fibrosis. Confirmatory biomarker diagnostic studies are not needed when
transitioning from NAFLD to MASLD. J Hepatol 2024;80:e51-2. DOI PubMed
76. Perseghin G. Exploring the in vivo mechanisms of action of glucokinase activators in type 2 diabetes. J Clin Endocrinol Metab
2010;95:4871-3. DOI PubMed
77. Lee CM, Yoon EL, Kim M, et al. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver
disease in primary care settings. Hepatology 2024;79:1393-400. DOI PubMed
78. Lee BP, Dodge JL, Terrault NA. National prevalence estimates for steatotic liver disease and subclassifications using consensus
nomenclature. Hepatology 24;79:666-73. DOI PubMed PMC
79. Israelsen M, Torp N, Johansen S, et al; GALAXY consortium. Validation of the new nomenclature of steatotic liver disease in
patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol
2024;9:218-28. DOI PubMed
80. Israelsen M, Torp N, Johansen S, Thiele M, Krag A. MetALD: new opportunities to understand the role of alcohol in steatotic liver
disease. Lancet Gastroenterol Hepatol 2023;8:866-8. DOI PubMed
81. Choe HJ, Moon JH, Kim W, Koo BK, Cho NH. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a
community-dwelling cohort study with 20-year follow-up. Metabolism 2024;153:155800. DOI PubMed
82. Han E, Lee BW, Kang ES, et al. Mortality in metabolic dysfunction-associated steatotic liver disease: a nationwide population-based
cohort study. Metabolism 2024;152:155789. DOI
83. Kim D, Wijarnpreecha K, Cholankeril G, Ahmed A. Metabolic dysfunction-associated steatotic liver disease and all-cause/cause-
specific mortality among adults in the United States. J Hepatol 2024;80:e79-81. DOI PubMed
84. Lee HH, Lee HA, Kim EJ, et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut
2024;73:533-40. DOI PubMed
85. Ciardullo S, Mantovani A, Morieri ML, Muraca E, Invernizzi P, Perseghin G. Impact of MASLD and MetALD on clinical outcomes:
a meta-analysis of preliminary evidence. Liver Int 2024;44:1762-7. DOI PubMed
86. Ramírez-Mejía MM, Jiménez-Gutiérrez C, Eslam M, George J, Méndez-Sánchez N. Breaking new ground: MASLD vs. MAFLD-
which holds the key for risk stratification? Hepatol Int 2024;18:168-78. DOI PubMed
87. De A, Bhagat N, Mehta M, Taneja S, Duseja A. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better
than MAFLD criteria for lean patients with NAFLD. J Hepatol 2024;80:e61-2. DOI PubMed
88. Pan Z, Shiha G, Esmat G, Méndez-Sánchez N, Eslam M. MAFLD predicts cardiovascular disease risk better than MASLD. Liver Int
2024;44:1567-74. DOI PubMed
89. Byrne CD, Targher G. MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding Metabolic
syndrome? Metab Target Organ Damage 2024;4:10. DOI
90. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607. DOI PubMed
91. National Cholesterol Education Program (US); Expert Panel On Detection, Treatment Of High Blood Cholesterol In Adults. Third
report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood
cholesterol in adults (Adult treatment panel III). The Program, 2002. Available from: https://books.google.com/books?hl=zh-CN&lr=
&id=VKpLAQAAIAAJ&oi=fnd&pg=PR2&dq=Third+report+of+the+national+cholesterol+education+program+(NCEP)+expert+
panel+on+detection,+evaluation,+and+treatment+of+high+blood+cholesterol+in+adults&ots=jXkq2nMHhu&sig=
07y2oicjyvSXt6TpFIho3hc-lSM#v=onepage&q=Third%20report%20of%20the%20national%20cholesterol%20education%
20program%20(NCEP)%20expert%20panel%20on%20detection%2C%20evaluation%2C%20and%20treatment%20of%20high%
20blood%20cholesterol%20in%20adults&f=false.
92. Alberti, KG, Eckel, RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the international
diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association;
world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation
2009;120:1640-5. DOI PubMed
93. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension,
dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94. DOI PubMed
94. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J
Physiol 1979;237:E214-23. DOI PubMed
95. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and
beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9. DOI PubMed
96. Perseghin G, Caumo A, Caloni M, Testolin G, Luzi L. Incorporation of the fasting plasma FFA concentration into QUICKI improves
its association with insulin sensitivity in nonobese individuals. J Clin Endocrinol Metab 2001;86:4776-81. DOI PubMed